NF1 glioblastoma clonal profiling reveals KMT2B mutations as potential somatic oncogenic events
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Although glioblastoma (GBM) is a common malignant brain tumor in older adults in the general population, the incidence of GBM is increased in the neurofibromatosis 1 (NF1) cancer predisposition syndrome, where it tends to arise decades earlier relative to its sporadic counterparts.1 In contrast to nonsyndromic GBM, NF1-GBM is presumed to arise in the setting of biallelic NF1 inactivation (germline variant and a subsequent somatic mutation).2 Because GBM is rare in patients with NF1, the limited number of cases reported has precluded an analysis of tumor ontogeny and evolution. Herein, we leveraged a unique opportunity in which multiple brain samples were obtained at autopsy from a young adult male with a clinical diagnosis of generalized NF1 (established at age 3 years) who died of GBM. When this 27-year-old man initially presented with behavioral changes, neuroimaging revealed a bithalamic tumor (figure 1A), which was pathologically classified as a grade IV astrocytoma (GBM) by stereotactic biopsy. He was treated with cranial radiation and chemotherapy, but exhibited progressive tumor growth and died 39 months after initial diagnosis. At autopsy under an approved IRB protocol, a representative non-neoplastic sample from an unaffected brain region and 5 distinct neoplastic lesions, including thalamus (4 independent samples), anterior commissure (2 independent samples), septum pellucidum (2 independent samples), amygdala (2 independent samples), and cerebellum (1 sample), were obtained.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Data availability: raw whole-exome sequencing data were deposited in the NCBI short read archive and can be publicly accessed via the accession number PRJNA540532. All other relevant data are included in the main text and data available from Dryad (supplementary data): doi.org/10.5061/dryad.t7109jf.
- Received June 12, 2019.
- Accepted in final form September 6, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
The biology of cutaneous neurofibromasConsensus recommendations for setting research prioritiesJean-Philippe Brosseau, Dominique C. Pichard, Eric H. Legius et al.Neurology, July 09, 2018 -
Article
Mutations in LZTR1 add to the complex heterogeneity of schwannomatosisMiriam J. Smith, Bertand Isidor, Christian Beetz et al.Neurology, December 05, 2014 -
Biomarkers
Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical UseChetan Bettegowda, Meena Upadhayaya, D. Gareth Evans et al.Neurology, July 06, 2021 -
Views & Reviews
The clinical and diagnostic implications mosaicism in the neurofibromatosesMartino Ruggieri, Susan M. Huson et al.Neurology, June 12, 2001